已上市钠-葡萄糖协同转运蛋白2抑制剂临床药动学特点比较  

Comparative Clinical Pharmacokinetics of Launched Sodium-glucose Cotransporter Type 2 Inhibitors

作　　者：谢少斐 张凤逸 邹珊 黄海燕 李纬 

机构地区：[1]南京长澳医药科技有限公司,南京210038

出　　处：《中国现代应用药学》2016年第4期517-520,共4页Chinese Journal of Modern Applied Pharmacy

摘　　要：钠-葡萄糖协同转运蛋白2(sodium-glucose cotransporter type 2,SGLT2)参与肾脏对90%葡萄糖滤过液的重吸收,在血糖调节中发挥重要作用。SGLT2抑制剂作为2型糖尿病治疗的新靶点,受到广泛关注。目前,已有卡格列净、达格列净、依帕列净、依格列净、托格列净、鲁格列净6种SGLT2抑制剂在美国和日本上市,本研究对已上市的SGLT2抑制剂临床药动学特点进行了比较和综述。Sodium-glucose cotransporter type 2（SGLT2） are responsible for reabsorption of 90% of the glucose filtered by the kidney, which plays a critical role in glucose control. SGLT2 inhibitors are widely concerned as a novel target for the treatment of type 2 diabetes mellitus. In recent years, canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, tofogliflozin and luseogliflozin have entered into the market in the USA and Japan. In this review, we will compare and summarize clinical pharmacokinetic characteristics of lanched SGLT2 inhibitors.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 2型糖尿病 药动学 

分 类 号：R969.1[医药卫生—药理学]